Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Patient perspective on immune oncology

221 views

Published on

LuCE President, Stefania Wallone presented patients perspective on the developement of new lung cancer drugs @IASLC Congress.

Published in: Health & Medicine
  • Be the first to comment

Patient perspective on immune oncology

  1. 1. Lung Cancer Europe Patient perspective on progress of lung cancer drugs 22nd of March, 2018
  2. 2. Data gathering and predictive analytics will become increasingly essential in idefining treatment value. Live tracking will increasingly reveal aspects of the patient journey which represent barriers to 'best practice' care delivery. The future of oncology - patient perspective Enter the age of personalized medicine - without a doubt one of the greatest trends to provide substantial patient and payer benefit for a generation. The healthcare industry is shifting away from the 'one- size-fits-all' concept, in the search for the most responsive patient subsets for each therapy or combinations regimen. This approach covers not only treatment but also the prevention of cancer. The future of oncology A focused approach to winning in 2030 KPMG
  3. 3. Personalized medicine - perspectives As the field of oncology continues to embrace personalized medicine with immuno-oncology and immunotherapy, patient activation is essential. genetics biomarkers PDL-1 CTLA-4 pathway Patient literacy - paradigm shifting
  4. 4. Personalized medicine - barriers What do oncology patients and caregivers know? Have they been provided with enough information to understand immunotherapy?Making choices in cancer treatment now depends on an understanding of genetics, gene expression and the immune system. We are already witnessing a dramatic reduction in eligible patient populations for novel treatments, as labels will only be awarded to highly-responding subsets, increasingly linked to companion diagnostics.
  5. 5. Personalized medicine - present & future A KPMG study forecasted that the number of indications per therapy will rise, as developers resist the narrowing of their potential patient pool, in an effort to maximize return on investment and recoup development costs. Anticipated number of oncology products with single vs multiple indications (2014-20)
  6. 6. Personalized medicine - patient perception In a changing world, where innovation enables patients to access information and insights more readily than ever before, they will fast become the most relevant stakeholder in the healthcare ecosystem, thus conferring the need for a change in emphasis from other players in the system – including pharma companies. Personalized medicine - expected patient outcomes - Understand future patient outcomes - Build understanding of patient journeys to better communicate value
  7. 7. Personalized medicine - patient perception Inspire Immunotherapy Awareness and Perceptions Survey, 2017 Survey snapshots:
  8. 8. Personalized medicine - patient perception Inspire Immunotherapy Awareness and Perceptions Survey, 2017 Interviewees :
  9. 9. Personalized medicine - patient perception Inspire Immunotherapy Awareness and Perceptions Survey, 2017 Main topics:
  10. 10. Personalized medicine - patient perception Inspire Immunotherapy Awareness and Perceptions Survey, 2017 Main topics:
  11. 11. Personalized medicine - patient perception Inspire Immunotherapy Awareness and Perceptions Survey, 2017 Main topics:

×